Skip to main content
. 2019 Oct 7;29(8):625–633. doi: 10.1089/cap.2018.0127

Table 3.

Laboratory Findings Corresponding to One Point in Time During Symptom Onset, Flare (Defined as Clinical Global Impressions-Severity Scale Equal to or Higher Than 4 and Marked as a Worsening Period in Patient Records), or During a Chronic-Static or Progressive Course, Compared with Population Norms

Laboratory findings Frequenciesa
CBC abnormalities 26/45 (58%)
Elevated ESR 6/43 (14%)
Elevated CRP 4/37 (11%)
Low ferritin 8/39 (21%)
Low vitamin D 10/36 (28%)
TSH abnormalities 4/40 (10%)
Low T4 0/40 (0%)
Anti-TPO 4/38 (11%)
Transglutaminase antibodies 2/40 (5%)
ANAs 7/41 (17%)
Histone antibodies 0/31 (0%)
Elevated SAA 3/22 (14%)
Complement activation 13/35 (37%)
Low IgG 4/36 (11%)
Low IgA 3/34 (9%)
Low IgM 0/34 (0%)
Elevated IL-1-β 0/25 (0%)
Elevated IL-6 1/25 (4%)
Elevated IL-8 0/25 (0%)
Elevated TNF-α 0/24 (0%)
Positive strep/throat culture 5/10 (50%)
a

These tests were only assessed in a subsample of participants.

ANAs, antinuclear antibodies; CBC, complete blood count; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; IgA, immunoglobulin A; IgG, immunoglobulin G; IgM, immunoglobulin M; IL, interleukin; SAA, serum amyloid A; TNF-α, tumor necrosis factor-α; TPO, thyroperoxidase; TSH, thyroid-stimulating hormone.